Semaglutide Research for Appetite Control
An evidence-based overview of research examining Semaglutide in the context of appetite control. This page synthesizes findings from peer-reviewed literature.
Research Summary
Reduced energy intake is one measured contributor to semaglutide-related weight loss. Specific POMC/CART and NPY/AgRP circuit effects are supported mainly by preclinical GLP-1 receptor research and should not be presented as a demonstrated human semaglutide mechanism. In one 20-week randomized mechanistic trial of 72 adults with obesity, ad libitum lunch intake was 35% lower with 2.4 mg injection than placebo (PMID:33269530). This meal-test result is not an estimate of daily intake across all patients. Participants also reported less hunger and greater fullness. Gastric-emptying effects can vary by study and time on treatment, so they should not be treated as the sole explanation for sustained weight loss. In the STEP 1 extension, weight regained after semaglutide and structured lifestyle intervention stopped. That follow-up does not isolate a single appetite mechanism or prove a permanent change in hunger signaling.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.